Close Menu

NEW YORK – Diagnostics firm OncoCyte said on Thursday that it has entered into definitive agreements with Pura Vida Investments, a healthcare focused registered investment advisor, and one other unnamed institutional investor, to purchase approximately $7.6 million of the company's common shares in a registered offering. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.